SCHEMBL4360469

SCHEMBL4360469

Cc1cc(C(=O)NC(=O)N(S)c2cccc(O[C@@H](C)c3ccccc3)c2)no1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.42
CYP2C19 P33261 3/20 0.42
CYP2D6 P10635 1/20 0.42
ALDH1A1 P00352 4/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2C9 P11712 2/20 0.41
LMNA P02545 2/20 0.41
HPGD P15428 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
HSD17B10 Q99714 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
SGPL1 O95470 2/20 0.39
MAPT P10636 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
PTGS2 P35354 1/20 0.39
GAA P10253 1/20 0.39
TSHR P16473 1/20 0.39
KLK7 P49862 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4373602 0.81 CYP1A2 (0.46) CYP1A2CYP2C19CYP2D6ALDH1A1LMNA
SCHEMBL4365221 0.78 ALDH1A1 (0.52) CYP1A2CYP2C19CYP2D6ALDH1A1LMNA
SCHEMBL4360463 0.78 ALDH1A1 (0.52) CYP1A2CYP2C19CYP2D6ALDH1A1LMNA
SCHEMBL4373593 0.78 ALDH1A1 (0.50) ALDH1A1LMNAHPGDHSD17B10MAPT
SCHEMBL4366242 0.77 MAPK14 (0.43) CYP1A2CYP2C19CYP2D6ALDH1A1CYP3A4
SCHEMBL4364673 0.76 MAPK14 (0.45) LMNASMN1; SMN2NPC1RAB9A
SCHEMBL4370528 0.66 TSHR (0.48) ALDH1A1LMNAHPGDL3MBTL1MAPT
SCHEMBL13956790 0.65 RAB9A (0.56) ALDH1A1LMNAHPGDMAPTMEN1
SCHEMBL11716646 0.65 MAPT (0.57) CYP1A2CYP2C19CYP2D6ALDH1A1LMNA
SCHEMBL2868192 0.63 GRM2 (0.47) CYP1A2CYP2C9MEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7476686-B2 Substituted aryl thioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2009-01-13 US claimed
US-20060014836-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication CHEN DAWEI 2006-01-19 US claimed
EP-1562895-A1 SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION Achillion Pharmaceuticals, Inc. (US) 2005-08-17 EP claimed
US-20040138205-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2004-07-15 US claimed
WO-2004046095-A1 SUBSTITUTED ARYL THIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS, INC. (US) 2004-06-03 WO claimed
US-7476686-B2 Substituted aryl thioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2009-01-13 US disclosed
US-7094807-B2 Substituted aryl thioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2006-08-22 US disclosed
US-20060014836-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication CHEN DAWEI 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138205-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication NAT1, PIGS, TPMT CYP1A2 267/4885CYP2C19 709/4885CYP2D6 372/4885
US-20060014836-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication NAT1, PIGS, SLC10A1 CYP1A2 187/4885CYP2C19 581/4885CYP2D6 351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.